1
Clinical Trials associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech) / Not yet recruitingPhase 2 A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E-2 (COVID-19 Beta/Omicron (BA.1/BQ.1.1/XBB.1) Variants S-Trimer Vaccine) in Population Previously Vaccinated With mRNA COVID-19 Vaccine
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines. A total of at least 600 subjects aged 3 years and older who were previously vaccinated with domestically licensed SARS-CoV-2 vaccines with recommended doses and immunization schedules are planned to be enrolled. Group A included 400 patients aged 18 years and above, and group B included 200 patients aged 3-17 years.
100 Clinical Results associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
100 Translational Medicine associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
100 Patents (Medical) associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
100 Deals associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)